Published in J Med Econ on June 16, 2011
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res (2013) 1.86
Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res (2014) 1.12
Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res (2015) 1.11
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis (2013) 1.05
Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv (2014) 0.88
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.82
A review of the value of innovation in inhalers for COPD and asthma. J Mark Access Health Policy (2015) 0.80
Significance of Medication History at the Time of Entry into the COPDGene Study: Relationship with Exacerbation and CT Metrics. COPD (2015) 0.80
Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression. Ann Am Thorac Soc (2016) 0.80
Switching treatments in COPD: implications for costs and treatment adherence. Int J Chron Obstruct Pulmon Dis (2015) 0.78
Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD). Patient (2014) 0.78
Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Prefer Adherence (2015) 0.77
Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. Cost Eff Resour Alloc (2015) 0.77
Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ Prim Care Respir Med (2016) 0.75
An evaluation of early medication use for COPD: a population-based cohort study. Int J Chron Obstruct Pulmon Dis (2016) 0.75
The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Asthma management among allergists in Italy: results from a survey. Clin Mol Allergy (2017) 0.75
Adherence and healthcare utilization among older adults with COPD and depression. Respir Med (2017) 0.75
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm (2011) 2.25
Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns. Eur J Pediatr (2013) 2.15
Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry (2012) 2.14
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ (2012) 2.05
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol (2006) 1.96
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis (2002) 1.73
Comparison of levels of large and small high-density lipoprotein cholesterol in Asian Indian men compared with Caucasian men in the Framingham Offspring Study. Am J Cardiol (2004) 1.55
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother (2011) 1.51
Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation (2008) 1.39
Risk behavior for transmission of human immunodeficiency virus (HIV) among HIV-seropositive individuals in an urban setting. Clin Infect Dis (2003) 1.37
Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia (2008) 1.32
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring) (2007) 1.28
Admissions for diabetic ketoacidosis in ethnic minority groups in a city hospital. Metabolism (2007) 1.28
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke (2006) 1.24
Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract (2007) 1.22
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
Hematologic reference values for African American children and adolescents. Am J Hematol (2007) 1.19
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics (2010) 1.10
Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am J Gastroenterol (2011) 1.10
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ (2011) 1.10
Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives. Circ Cardiovasc Qual Outcomes (2012) 1.09
Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health (2007) 1.08
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med (2012) 1.08
Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 1.07
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. J Manag Care Spec Pharm (2015) 1.06
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS One (2011) 1.05
Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry (2013) 1.03
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health (2012) 1.03
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther (2009) 1.02
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther (2012) 1.01
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin (2007) 1.01
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol (2011) 0.99
Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin (2009) 0.98
Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). Curr Med Res Opin (2014) 0.95
Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin (2009) 0.94
Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther (2012) 0.94
Simple techniques to reduce bowel activity in cardiac SPECT imaging. Nucl Med Commun (2004) 0.93
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig (2011) 0.92
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin (2011) 0.92
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol (2010) 0.92
Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis (2013) 0.92
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav (2011) 0.90
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol (2009) 0.90
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med (2011) 0.90
Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. Vaccine (2012) 0.90
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol (2011) 0.90
The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes (2013) 0.89
Adult ADHD patient experiences of impairment, service provision and clinical management in England: a qualitative study. BMC Health Serv Res (2013) 0.89
Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs (2012) 0.89
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin (2013) 0.89
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med (2006) 0.88
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf (2012) 0.86
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol (2012) 0.86
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin (2014) 0.86
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin (2010) 0.85
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol (2009) 0.85
Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin (2007) 0.85
Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol (2012) 0.85
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ (2013) 0.84
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. J Med Econ (2013) 0.84
Association of heart rate response with scan and left ventricular function on adenosine myocardial perfusion imaging. Am J Cardiol (2002) 0.84
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol (2012) 0.83
Accuracy of the ratio of triglycerides to high-density lipoprotein cholesterol for predicting low-density lipoprotein cholesterol particle sizes, phenotype B, and particle concentrations among Asian Indians. Am J Cardiol (2006) 0.83
Development and validation of a claims-based prediction model for COPD severity. Respir Med (2013) 0.83
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ (2013) 0.82
Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma (2007) 0.82
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. J Med Econ (2014) 0.82
Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care (2013) 0.82
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin (2012) 0.82
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin (2012) 0.82
Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry (2014) 0.81
The role of health economics and outcomes research in health care reform in China. Pharmacoeconomics (2014) 0.81
Prevalence and risk of developing comorbid conditions in patients with chronic constipation. Curr Med Res Opin (2014) 0.81
Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus. Curr Med Res Opin (2010) 0.81
Comparison of high-density and low-density lipoprotein cholesterol subclasses and sizes in Asian Indian women with Caucasian women from the Framingham Offspring Study. Clin Cardiol (2005) 0.81
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology (2010) 0.81
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ (2011) 0.81
Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital. J Natl Med Assoc (2007) 0.81
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Curr Med Res Opin (2015) 0.81
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics (2012) 0.80
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev (2013) 0.80